IRGD-modified erythrocyte membrane biomimetic temozolomide nanodots for the treatment of glioblastoma.

The cross of the blood-brain barrier (BBB) for conventional anticancer drugs is still a big challenge in treating glioma. The biomimetic nanoparticle delivery system has attracted increasing attention and is a promising future for crossing the BBB. Herein, we construct a multifunctional biomimetic nanoplatform using erythrocyte membrane (EM) with tumor-penetrating peptide iRGD (CRGDK/RGPD/EC) as a delivery, and the inner core loaded with chemotherapeutic drug temozolomide (TMZ). The resulting biomimetic nanoparticle has perfect biocompatibility and stealth ability, which will provide more chances to escape the reticuloendothelial system (RES) entrapment, and increase the opportunity to enter the tumor site. Moreover, the decorated iRGD has been extensively used to active targeting and deliver therapeutic agents across the BBB into gliomas tissue. We show that this biomimetic delivery of TMZ with a diameter of 22 nm efficiently slowed the growth of glioblastoma multiforme (GBM) and increase survival rate of the 30-day from 0 to 100 %.